Article
Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Theranostics - 1 Jan 2020
Chen Peng, Li Xuejie, Zhang Ruonan, Liu Shuiping, Xiang Yu, Zhang Mingming, Chen Xiaying, Pan Ting, Yan Lili, Feng Jiao, Duan Ting, Wang Da, Chen Bi, Jin Ting, Wang Wengang, Chen Liuxi, Huang Xingxing, Zhang Wenzheng, Sun Yitian, Li Guohua, Kong Lingpan, Chen Xiaohui, Li Yongqiang, Yang Zuyi, Zhang Qin, Zhuo Lvjia, Sui Xinbing, Xie Tian
Abstract excerpt
Background and Purpose: RAS mutations limit the effectiveness of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in combination with chemotherapy for metastatic colorectal cancer (mCRC) patients. Therefore, new cell death forms have focused on identifying indirect targets to inhibit Ras-induced oncogenesis. Recently, emerging evidence has shown the potential of triggering ferroptosis for cancer...
Topics
Join the communities discussing this publication.